No Data
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Is There Now An Opportunity In Gushengtang Holdings Limited (HKG:2273)?
Gu Shengtang's Tu Zhi Liang: AI-assisted diagnosis and treatment + internet plus-related hospital + innovative chinese patent medicine, three-pronged approach to help traditional Chinese medicine reach the world.
Recently, Tu Zhiliang, the founder and chairman of Gushengtang, was successfully selected as one of the "2024 Forbes China's Top 100 Most Influential Chinese Elite". The official Forbes account published a special interview with Mr. Tu Zhiliang in the headline position. The full text is as follows: From establishing Gushengtang in 2010 to ringing the bell at the Hong Kong Stock Exchange in 2021, Tu Zhiliang has shown a breakthrough path for the entire traditional Chinese medicine industry. As the "first stock of Chinese medicine medical services", the success of Gushengtang has not only promoted the modernization and international development of traditional Chinese medicine, but also helped the entire Chinese medicine industry achieve an important "transformation". Looking back on this entrepreneurial experience, Tu Zhiliang said, "At the beginning...
Gushengtang to Repurchase Shares for Up to HK$200 Million
In 2023, the subsidiary of china re has original premium income exceeding 40 billion yuan. Gushengtang plans to repurchase up to 0.2 billion Hong Kong dollars | Highlights from the Hong Kong stock market announcement on November 22.
①The annual original premium income of china re's subsidiary exceeded 40 billion yuan, what are the highlights? ②Kangshengtang plans to repurchase up to 0.2 billion Hong Kong dollars, which other companies are actively repurchasing?
Koseido (02273) resolves to exercise buyback authorization, planning to repurchase shares up to a maximum of 0.2 billion Hong Kong dollars.
Kosho-do (02273) announced that according to the shareholder on June 18, 2024 at the shareholder's annual meeting...
Investors Give Zhejiang Crystal-Optech Co., Ltd (SZSE:002273) Shares A 27% Hiding
No Data
